Overview
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2
Status:
Completed
Completed
Trial end date:
2020-09-08
2020-09-08
Target enrollment:
0
0
Participant gender:
All
All
Summary
Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover studyPhase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Daewon Pharmaceutical Co., Ltd.
Criteria
Inclusion Criteria:- Healthy Volunteers who are ≥19 years old
- Body weight ≥50.0 kg and BMI between 18.0 and 30.0 kg/m2 and
Exclusion Criteria:
- Clinically significant Medical History
- In the case of women, pregnant(Urine-HCG positive) or lactating women